natgillin/translations-raw huggingface dataset:
The antibody or antibody fragment according to claim 3 for use in the treatment of cancer or the use of claim 11, wherein the lung cancer is selected from the group consisting of squamous cell lung carcinoma, lung adenocarcinoma, carcinoid, small cell lung cancer or non-small cell lung cancer. 
Protutijelo ili fragment protutijela prema zahtjevu 3 za uporabu za liječenje raka ili uporaba prema zahtjevu 11, naznačeno time što je rak pluća odabran iz skupine koju čine karcinom pluća skvamoznih stanica, adenokarcinom pluća, karcinoid, karcinom pluća malih stanica ili karcinom pluća ne-malih stanica.
The antibody or antibody fragment according to claim 1 for use in therapy, or the antibody or antibody fragment according to claim 2 for use in the treatment of cancer, or the use according to claim 10, wherein the variants of the ectodomain possess at least 90%, at least 95, 96, 97, 98 or 99% sequence identity with the polypeptides of SEQ ID NO 147, 148 and 299. 
Protutijelo ili fragment protutijela prema zahtjevu 1 za uporabu u terapiji, ili protutijelo ili fragment protutijela prema zahtjevu 2 za uporabu za liječenje raka, ili uporaba prema zahtjevu 10, naznačeno time što varijante ektodomena posjeduju najmanje 90%, najmanje 95, 96, 97, 98 ili 99% identičnosti sekvence s polipeptidima iz SEQ ID NO 147, 148 i 299.
A microencapsulated bacterial consortium, characterized in that it comprises: (a) three different strains of commercially available lactic-acid bacteria; b) encapsulating agents; c) prebiotics; and d) trehalose; 
Mikroenkapsulirani bakterijski konzorcij, naznačen time što sadrži: (a) tri različita soja komercijalno dostupnih bakterija mliječne kiseline; b) agense za enkapsulaciju; c) prebiotike; i d) trehalozu; u kombinaciji s proteolitičkim enzimom bakterijskog porijekla i proteolitičkim enzimom gljivičnog porijekla.
A microencapsulated bacterial consortium, according to claim 1, wherein the three strains of lactic-acid bacteria are Lactobacillus plantarum ATCC 8014, Lactobacillus sanfranciscensis ATCC 27652 and Lactobacillus brevis ATCC 14869. 
Mikroenkapsulirani bakterijski konzorcij, prema zahtjevu 1, pri čemu su tri soja bakterija mliječne kiseline Lactobacillus plantarum ATCC 8014, Lactobacillus sanfranciscensis ATCC 27652 i Lactobacillus brevis ATCC 14869.
A microencapsulated bacterial consortium, according to claim 1, wherein the encapsulating agents are selected from the group comprising isolated protein from milk serum with 90 % protein, maltodextrin with a dextrose equivalent of 10, arabic gum, mesquite gum, sodium alginate, pectin, soy isolated protein, casein and combinations thereof. 
Mikroenkapsulirani bakterijski konzorcij, prema zahtjevu 1, pri čemu su agensi za enkapsulaciju izabrani iz skupine koja sadrži izolirani protein iz mliječnog seruma s 90 % proteina, maltodekstrin s ekvivalentom dekstroze od 10, gumu arabiku, mesquite gumu, natrijev alginat, pektin, izolirani protein soje, kazein i njihove kombinacije.
A microencapsulated bacterial consortium, according to claim 1, wherein the prebiotics are selected from the group comprising polydextrose, inulin and maguey honey. 
Mikroenkapsulirani bakterijski konzorcij, prema zahtjevu 1, pri čemu su prebiotici izabrani iz skupine koja sadrži polidekstrozu, inulin i med agave.
A microencapsulated bacterial consortium, according to claim 5, wherein the prebiotic is maguey honey. 
Mikroenkapsulirani bakterijski konzorcij, prema zahtjevu 5, pri čemu je prebiotik med agave.
A microencapsulated bacterial consortium, according to claim 1, wherein the proteolytic enzyme of bacterial origin and the proteolytic enzyme of fungal origin are selected from enzymes commonly used for baking. 
Mikroenkapsulirani bakterijski konzorcij, prema zahtjevu 1, pri čemu su proteolitički enzim bakterijskog porijekla i proteolitički enzim gljivičnog porijekla odabrani od enzima koji se obično koriste za pečenje.
A microencapsulated bacterial consortium, according to claim 1, comprising: a) Lactobacillus plantarum ATCC 8014; b) Lactobacillus sanfranciscensis ATCC 27652; c) Lactobacillus brevis ATCC 14869; d) isolated protein from milk serum with 90 % protein; e) maltodextrin with a dextrose equivalent of 10; f) arabic gum; g) maguey honey; and h) trehalose; 
Mikroenkapsulirani bakterijski konzorcij, prema zahtjevu 1, koji sadrži: a) Lactobacillus plantarum ATCC 8014; b) Lactobacillus sanfranciscensis ATCC 27652; c) Lactobacillus brevis ATCC 14869; d) izolirani protein iz mliječnog seruma s 90 % proteina; e) maltodekstrin s ekvivalentom dekstroze od 10; f) gumu arabiku; g) med agave; i h) trehalozu;
A microencapsulated bacterial consortium, according to claim 8, comprising: a) Lactobacillus plantarum ATCC 8014; b) Lactobacillus sanfranciscensis ATCC 27652; c) Lactobacillus brevis ATCC 14869; d) from 40 to 60 % of isolated protein from milk serum with 90 % protein; e) from 10 to 20 % of maltodextrin with a dextrose equivalent of 10; f) from 20 to 80 % arabic gum; g) from 1 to 10 % of maguey honey; and h) trehalose; 
Mikroenkapsulirani bakterijski konzorcij, prema zahtjevu 8, koji sadrži: a) Lactobacillus plantarum ATCC 8014; b) Lactobacillus sanfranciscensis ATCC 27652; c) Lactobacillus brevis ATCC 14869; d) od 40 do 60 % izoliranog proteina iz mliječnog seruma s 90 % proteina; e) od 10 do 20 % maltodekstrina s ekvivalentom dekstroze od 10; f) od 20 do 80 % gume arabike; g) od 1 do 10 % meda agave; i h) trehalozu;
separately reactivate each strain of lactic-acid bacteria; 
zasebno reaktiviranje svakog soja bakterija mliječne kiseline;
dissolving the encapsulating agents in water, at the proper ratios to have 20 to 30 % of dissolved solids; 
otapanje agensa za enkapsulaciju u vodi, u ispravnim omjerima kako bi se dobilo 20 do 30 % otopljenih krutina;
A sourdough characterized by comprising the microencapsulated bacterial consortium of claim 1, characterized in that it comprises: (a) three different strains of commercially available lactic-acid bacteria; b) encapsulating agents; c) prebiotics; and d) trehalose; in combination with a proteolytic enzyme of bacterial origin and a proteolytic enzyme of fungal origin, wherein sourdough has a gluten concentration lower than 20 ppm. 
Kiselo tijesto naznačeno time što sadrži mikroenkapsulirani bakterijski konzorcij prema zahtjevu 1, naznačeno time što sadrži: (a) tri različita soja komercijalno dostupnih bakterija mliječne kiseline; b) agense za enkapsulaciju; c) prebiotike; i d) trehalozu; u kombinaciji s proteolitičkim enzimom bakterijskog porijekla i proteolitičkim enzimom gljivičnog porijekla, pri čemu kiselo tijesto ima koncentraciju glutena nižu od 20 ppm.
A sourdough, according to claim 12, having a gluten concentration lower than 10 ppm. 
Kiselo tijesto, prema zahtjevu 12, koje ima koncentraciju glutena nižu od 10 ppm.
A sourdough according to claim 12, wherein the gluten concentration lower than 20 ppm is achieved after 3 hours of fermentation, preferably after 31 hours of fermentation. 
Kiselo tijesto prema zahtjevu 12, pri čemu je koncentracija glutena niža od 20 ppm postignuta nakon 3 sata fermentacije, poželjno nakon 31 sata fermentacije.
A process to make a sourdough from a microencapsulated bacterial consortium of claim 1, in combination with a proteolytic enzyme of bacterial origin and a proteolytic enzyme of fungal origin, comprising the following steps: 
Postupak proizvodnje kiselog tijesta iz mikroenkapsuliranog bakterijskog konzorcija prema zahtjevu 1, u kombinaciji s proteolitičkim enzimom bakterijskog porijekla i proteolitičkim enzimom gljivičnog porijekla, koji sadrži sljedeće korake:
mixing 30 to 60 % flour with 40 to 80 % water to obtain a dough with a dough yielding from 150 to 475, preferably from 150 to 160; 
miješanje 30 do 60 % brašna s 40 do 80 % vode kako bi se dobilo tijesto s izbrašnjavanjem od 150 do 475, poželjno od 150 do 160;
ii) adding 0.005 to 0.03 % proteolytic enzyme of bacterial origin and 0.001 to 0.02 % proteolytic enzyme of fungal origin previously dissolved in the kneading water; 
ii) dodavanje 0,005 do 0,03 % proteolitičkog enzima bakterijskog porijekla i 0,001 do 0,02 % proteolitičkog enzima gljivičnog porijekla prethodno rastopljenih u vodi za miješenje;
A process to make a sourdough, according to claim 15, wherein the flour used in step i) is selected from wheat flour, rye flour and oatmeal flour. 
Postupak proizvodnje kiselog tijesta, prema zahtjevu 15, pri čemu je brašno korišteno u koraku i) odabrano od pšeničnog brašna, raženog brašna i zobenog brašna.
A process to make a sourdough, according to claim 15, wherein the fermentation is carried out during 31 hours, at a temperature of 35 °C and a relative humidity of 76 %. 
Postupak proizvodnje kiselog tijesta, prema zahtjevu 15, pri čemu se fermentacija provodi kroz 31 sat, pri temperaturi od 35 oC i relativnoj vlažnosti od 76 %.
A bakery product made from the sourdough of claim 12, which is gluten-free. 
Pekarski proizvod proizveden od kiselog tijesta prema zahtjevu 12, koji je bez glutena.
A baking product according to claim 19, which is sweet bread. 
Proizvod pečenja prema zahtjevu 19, koji je slatki kruh.
A method according to claim 1, comprising the step of comparing the conditioning parameters with at last one predetermined reference magnitude GE(i) associated to a predetermined category of food-grade wood, and determining the belonging of the wooden part-components (2) to said predetermined category of food-grade wood on the basis of said comparison. 
Postupak sukladno patentnom zahtjevu 1, obuhvaća korak usporedbe parametara kondicioniranja s najmanje jednom unaprijed određenom referentnom magnitutdom GE(i) povezanom s predodređenom kategorijom drveta za uporabu u prehrambenoj industriji, i određivanje pripadnosti drvenog dijela (2) navedenoj predodređenoj kategoriji drveta za uporabu u prehrambenoj industriji na temelju navedene usporedbe.
A method according to claim 1 or 2, wherein said aromatic substances further comprise vanillin and/or volatile phenols and/or aldehydes. 
Postupak sukladno patentnom zahtjevu 1 ili 2, pri čemu aromatske tvari nadalje sadrže vanilin i/ili hlapljive fenole i/ili aldehide.
A method according to any one of the previous claims, comprising the steps of determining said conditioning parameters by analysis / processing algorithms by means of predetermined correlation functions on the basis of the measured spectrum, wherein said correlation functions associated to the conditioning parameters are determined by means of multivariate PCA (Principal Component Analysis) or PLS (Partial Least Squares) statistic processing methods / tests, applied to a series of sample data associated to the conditioning parameters to be detected and to the corresponding wavelength bands. 
Postupak sukladno bilo kojem od prethodnih patentnih zahtjeva, obuhvaća korake određivanja navedenog uvjetovanja parametara algoritmima za analizu/obradu pomoću unaprijed određenih funkcija korelacijskih funkcija temeljem mjernog spektra, pri čemu navedene korelacijske funkcije na osnovi mjernog spektra, pri čemu navedene korelacijske funkcije povezane s kondicioniranjem određuju pomoću multivarijantne PCA (analize glavnih komponenti) ili PLS (parcijalne regresije najmanjih kvadrata) statističkih postupaka obrade/ testova, primenjenih na niz uzoraka podataka povezane s parametrima kondicioniranja koje treba detektirati i s odgovarajućim rasponima valne duljine.
An installation according to claim 1, characterised in that the installation (1) comprises windmills (4) in pairs. 
Instalacija prema zahtjevu 1, naznačena time što instalacija (1) sadrži vjetrenjače (4) u parovima.
An installation according to claim 2, characterised in that said windmills (4) have counter-rotating rotors. 
Instalacija prema zahtjevu 2, naznačena time što navedene vjetrenjače (4) imaju protusmjerno rotirajuće rotore.
An installation according to claim 1, characterised in that the installation (1) is anchored with limited sway. 
Instalacija prema zahtjevu 1, naznačena time što je instalacija (1) usidrena s ograničenim nagibom.
An installation according to claim 1, characterised in that the piston (36) of the pump (6) is connected to a float (48) by means of a connecting stay (50). 
Instalacija prema zahtjevu 1, naznačena time što je klip (36) crpke (6) povezan s plovkom (48) pomoću spojnog držača (50).
An installation according to claim 1, characterised in that the pump (6) is double acting. 
Instalacija prema zahtjevu 1, naznačena time što je crpka (6) dvostruko djelujuća.
An installation according to claim 1, characterised in that the piston rod (30) of the pump (6) is provided with an inflow opening (38). 
Instalacija prema zahtjevu 1, naznačena time što je klipnjača (30) crpke (6) opremljena s ulaznim otvorom (38).
An installation according to claim 1, characterised in that damper plates (22) are dis-posed horizontally in a lower portion of the frame structure (2) of the installation (1). 
Instalacija prema zahtjevu 1, naznačena time što su prigušne ploče (22) postavljene vodoravno u donjem dijelu konstrukcije okvira (2) instalacije (1).
The compound as claimed in any one of the claims 1 to 5, wherein the compound is selected from the group consisting of: 
Spoj sukladno bilo kojem od zahtjeva 1 do 5, pri čemu je spoj odabran iz skupine sastavljene iz slijedećih:
The pharmaceutical composition as claimed in claim 8, for the use in treatment of clinical conditions mediated through muscarinic M1 receptor selected from the group consisting of Alzheimer's disease, schizophrenia, cognitive disorders, pain or sleep disorders. 
Farmaceutski pripravak sukladno zahtjevu 8, radi liječenju kliničkih stanja uzrokovanih muskarinskim M1 receptorom odabranih iz skupine sastavljene od Alzheimerove bolesti, Shizofrenije, kognitivnih poremećaja, boli ili poremećaja spavanja.
A compound as claimed in any one of the claims 1 to 7, for use in the treatment of a disorder related to muscarinic M1 receptor is selected from the group consisting of Alzheimer's disease, schizophrenia, cognitive disorders, pain or sleep disorders. 
Spoj sukladno bilo kojem od zahtjeva 1 do 7, radi liječenju kliničkih stanja uzrokovanih muskarinskim M1 receptorom odabranih iz skupine sastavljene od Alzheimerove bolesti, Shizofrenije, kognitivnih poremećaja, boli ili poremećaja spavanja.
The compound for use as claimed in claim 11, wherein the disorder related to muscarinic M1 receptor selected from the group consisting of Alzheimer's disease, schizophrenia, cognitive disorders, pain or sleep disorders. 
Spoj radi primjene sukladno zahtjevu 11, pri čemu je poremećaj povezan s muskarinskim M1 receptorom odabranih iz skupine sastavljene od Alzheimerove bolesti, Shizofrenije, kognitivnih poremećaja, boli ili poremećaja spavanja.
A composition comprising a bacterial strain of the genus Blautia hydrogenotrophica having a 16s rRNA sequence that is at least 95% identical to SEQ ID NO:5, for use in a method of treating or preventing diarrhea and/or constipation. 
Kompozicija koja obuhvaća bakterijsku vrstu iz roda Blautia hydrogenotrophica koja ima sekvencu 16s rRNK koja je najmanje 95% identična sa SEQ ID NO:5, za upotrebu u postupku liječenja ili prevencije dijareje i/ili konstipacije.
The composition for use of claim 2, wherein the inflammatory disease is of the small intestine, colon or rectum. 
Kompozicija za upotrebu prema zahtjevu 2, gdje je upalna bolest tankog crijeva, debelog crijeva ili rektuma.
in a method of treating diarrhea wherein the subject has diarrhea without constipation; and/or 
u postupku liječenja dijareje pri čemu subjekt ima dijareju bez konstipacije; i/ili
in a method of treating constipation wherein the subject has constipation without diarrhea 
u postupku liječenja konstipacije pri čemu subjekt ima konstipaciju bez dijareje
The composition for use of claim 1 wherein the diarrhea is associated with Enterobacteriaceae infection. 
Kompozicija za upotrebu prema zahtjevu 1 pri čemu je dijareja povezana sa infekcijom Enterobacteriaceae.
the bacterial strain is viable; and/or 
bakterijska vrsta je održiva; i/ili
the composition comprises a single strain of the genus Blautia; and/or 
kompozicija obuhvaća jednu vrstu iz roda Blautia; i/ili
A computer program comprising instructions for carrying out all the steps of the method according to any preceding method claim, when said computer program is executed on a computer system. 
Računalni program, naznačen time što sadrži upute o provođenju svih koraka postupka u skladu s bilo kojim od prethodnih patentnih zahtjeva na postupak, kada se navedeni računalni program izvršava na računalnom sustavu.
characterised in that: the first hinge segment (20) includes at least one bearing surface (21); 
naznačen time što: prvi segment šarke (20) uključuje najmanje jednu nosivu površinu (21);
A dry powder inhaler of claim 1, wherein the assembled inhaler consists of no more than three integral components: the first component being constituted by the mouthpiece (8) and body (3) locked together to form a single integral component, the second being constituted by the tray (2) and the third being constituted by the cover (4). 
Inhalator suhog praha prema zahtjevu 1, naznačen time što se sastavljeni inhalator sastoji od najviše tri integralne komponente: prva komponenta se sastoji od usnika (8) i tijela (3) zaključanih zajedno da tvore jedan integralni dio, a drugu čine pladanj (2) i treći je poklopac (4).
The method of claim 1, wherein the filtering control is included in a transaction begin instruction, the transaction begin instruction being one transaction begin instruction of a plurality of transaction begin instructions used to create a nest of transactions, and wherein one or more of the transaction begin instructions include a filtering control, and wherein the filtering control employed is a highest value of the one or more filtering controls. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je kontrola filtriranja prekidanja programa uključena u uputi o početku transakcije (216), gdje je uputa o početku transakcije jedna uputa o početku transakcije između više uputa o početku transakcije (600, 602, 604), upotrijebljenih za stvaranje gnijezda transakcija, gdje jedna ili više uputa o početku transakcije uključuju kontrolu filtriranja prekidanja programa, te gdje je upotrijebljena kontrola filtriranja prekidanja programa najviša vrijednost između jedne ili više kontrola filtriranja prekidanja programa.
The method of claim 1, wherein the transaction is a constrained transaction and the filtering control is set to a default value. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što je transakcija ograničena transakcija, a kontrola filtriranja prekidanja programa je podešena na zadanu vrijednost.
The siRNA according to claim 1 or 2, wherein 1 to 10 consecutive nucleotides excluding an overhang nucleotide from the 3' terminus of the sense strand of the siRNA are converted into DNA. 
siRNA u skladu s patentnim zahtjevom 1, naznačena time, da se 1 do 10 uzastopnih nukleotida s iznimkom izbočenog nukleotida iz 3' terminusa sens lanca siRNA, pretvaraju u DNA.
wherein a compound of formula (5): is allowed to react with a reducing agent, such as hydrogen for example, optionally in the presence of a catalyst, such as a bimetallic catalyst such as platinum/iron on charcoal for example, particularly 1% Pt/0.2% Fe/C, which is water-wetted, optionally dissolved in a solvent or in suspension in a solvent, such as tetrahydrofuran for example, thereby providing a compound of formula (6). 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time što je navedeni korak A5 u prisutnosti katalizatora, kao što je bimetalni katalizator kao što je platina/željezo na ugljenu na primjer, naročito 1% Pt/0.2% Fe/C, koji je navlažen vodom, po izboru otopljen u otapalu ili u suspenziji u otapalu, kao što je na primjer tetrahidrofuran.
wherein a compound of formula (5): is allowed to react with hydrogen in the presence of a bimetallic catalyst, which is 1% Pt/0.2% Fe/C which is water-wetted in suspension in tetrahydrofuran, thereby providing a compound of formula (6). 
pri čemu spoj s formulom (5): ostavljen da reagira s vodikom u prisutnosti bimetalnog katalizatora, koji je 1% Pt/0.2% Fe/C koji je navlažen vodom u suspenziji u tetrahidrofuranu, čime se dobiva spoj formule (6).
wherein a compound of formula (4): is allowed to react with ethylenediamine, optionally in the presence of N-bromosuccinimide, optionally in a solvent mixture, such as methanol and acetonitrile for example, thereby providing a compound of formula (5). 
pri čemu je spoj s formulom (4): ostavljen da reagira s etilendiaminom, čime se dobiva spoj formule (5). Postupak prema zahtjevu 17, naznačen time što je korak A4 u prisutnosti N-bromosukcinimida.
The method according to any one of claims 1 to 3, wherein said compound of formula (4): is prepared by the following step A3, wherein a compound of formula (3): optionally in a solvent, such as N,N-dimethylformamide for example, optionally in the presence of a base, such as potassium carbonate for example, is allowed to react with benzyl bromide, optionally with heating, such as under reflux for example, thereby providing a compound of formula (4). 
Postupak prema zahtjevu 17 ili 18, naznačen time što je korak A4 u smjesi otapala, kao što je na primjer metanol i acetonitril. Postupak prema bilo kojem od zahtjeva 17 do 19, naznačen time što se navedeni spoj s formulom (4): priprema pomoću slijedećeg koraka A3, pri čemu je spoj s formulom (3): ostavljen da reagira s benzil bromidom, čime se dobiva spoj formule (4).
The method according to any one of claims 1 to 5, wherein said compound of formula (2): is prepared by the following step A1, wherein a compound of formula (1): is allowed to react, in solution in a solvent, such as dichloromethane for example, with nitric acid and sulphuric acid, thereby providing a compound of formula (2). 
Postupak prema bilo kojem od zahtjeva 24 do 26, naznačen time što se navedeni spoj s formulom (2): priprema pomoću slijedećeg koraka A1, pri čemu je spoj s formulom (1): ostavljen da reagira, u otopini u otapalu, s dušičnom kiselinom i sumpornom kiselinom, čime se dobiva spoj formule (2).
wherein a compound of formula (9a): is: 
pri čemu je spoj s formulom (9a):
adding water and an aqueous solution of a base, such as sodium hydroxide for example, followed by heating, then, 
dodavanje gvanidin hidroklorida, uz zagrijavanje, zatim, dodavanje vode i vodene otopine baze, uz zagrijavanje, zatim,
wherein copanlisib, of formula (10): is allowed to react with hydrogen chloride, optionally hydrochloric acid, thereby providing copanlisib dihydrochloride (11): 
pri čemu je kopanlisib, s formulom (10): ostavljen da reagira s hidrogen kloridom, čime se dobiva kopanlisib dihidroklorid (11):
Rc is, at each occurrence, independently selected from: C3-6 cycloalkyl substituted with 0-2 Rd, C3-6 cycloalkenyl substituted with 0-2 Rd, —(CH2)m-(phenyl substituted with 0-3 Rd), and (a 5- to 6-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NRe, O, and S; wherein said heterocycle is substituted with 0-2 Rd); 
Rc je, pri svakom pojavljivanju, nezavisno odabrano od: C3-6 cikloalkil supstituiran sa 0-2 Rd, C3-6 cikloalkenil supstituiran sa 0-2 Rd, -(CH2)m-(fenil supstituiran sa 0-3 Rd), i (5- do 6-očlani heterociklus koji sadrži ugljikove atome i 1-4 heteroatoma odabrana od N, NRe, O, i S; gdje spomenuti heterociklus je supstituiran sa 0-2 Rd);
is independently selected from: halogen, C1-6 alkyl with 0-1 OH, C1-4 alkoxy, C1-4 haloalkoxy, CO(C1-4 alkyl), N(C1-4 alkyl)2, and —(CH2)0-1—C3-6 cycloalkyl; is independently selected from: halogen, C1-4 alkyl and C1-4 alkoxy; alternatively, R6 and R7, together with the carbon atoms to which they are attached, combine to form a 6-membered carbocyclic ring; 
je nezavisno odabrano od: halogen, C1-6 alkil sa 0-1 OH, C1-4 alkoksi, C1-4 haloalkoksi, CO(C1-4 alkil), N(C1-4 alkil)2, i -(CH2)0-1-C3-6 cikloalkil; je nezavisno odabrano od: halogen, C1-4 alkil i C1-4 alkoksi; alternativno, R6 i R7, zajedno sa ugljikovim atomima za koje su oni vezani, se kombiniraju da formiraju 6-očlani karbociklični prsten;